Pharmalittle: We're reading about a GSK deal for a drug from China, job losses in the U.S., and more

ByEd Silverman

Sept. 15, 2026

Pharmalot Columnist, Senior Writer

Ed Silverman

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morningPharmalittle newsletterand the afternoonPharmalot newsletter.

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they are happily snoozing in their respective corners. As for us, we are firing up the trusty kettle for another cuppa stimulation. Our choice today is ginger peach. Of course, you are invited to join us. For the full experience, we are now hawking replicas —take a look. Meanwhile, here are a few items of interest. As always, do keep in touch. We appreciate feedback, criticism, and tips. …

Doctors, veterans, pharmacists, and therapists urged the U.S. Food and Drug Administration to establish clear safety ‌and access standards for psychedelic therapies during a four-hour public meeting on Monday convened by the agency amid efforts to speed development,Reutersreports. The hearing was the latest in a months-long push by the Trump administration to bring qualified psychedelic drug programs to market. Discussions at the ​meeting focused on practical issues that could shape how psychedelic therapies are tested and delivered, including provider training ​and credentials, patient screening and monitoring, access and reimbursement, clinic capacity, and collecting long-term ⁠safety data.

Advertisement

GSK has continued its drive to bulk up its pipeline, taking global rights to a multiple myeloma treatment, which was developed by China’s Chimagen Biosciences, for up to $750 million,Pharmaphorumwrites. The deal focuses on a “potential first-in-class” trispecific T-cell engager that, according to GSK, promises to combine good targeting of multiple myeloma cells but also offer improved safety compared to other TCEs for the blood cancer, which it says have suffered from “difficult tolerability profiles.” Chimagen’s unidentified candidate is currently in preclinical-stage development and due to start human testing next year.

STAT+ Exclusive Story

Already have an account?Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account?Log in

Monthly

$39

Totals $468 per year

Totals $468 per year

Starter

$30

for 3 months, then $399/year

Then $399/year

Annual

$399

Save 15%

Save 15%

11+ Users

Custom

Savings start at 25%!

Savings start at 25%!

2-10 Users

$300

Annually per user

$300 Annually per user

To read the rest of this story subscribe to STAT+.

,

1. Ed Silverman

   Pharmalot Columnist, Senior Writer

   Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morningPharmalittle newsletterand the afternoonPharmalot newsletter.

Newsletter

Understand how science, health policy, and medicine shape the world every day